Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38

Cephalalgia

Volumn 32, Issue 4, 2012, Pages 337-345

  Baun, Michael ^a   Pedersen, Martin Holst Friborg ^b   Olesen, Jes ^a   Jansen Olesen, Inger ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Mast cells; migraine; neuropeptide; PAC1 receptor; PACAP; VIP

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; BETA N ACETYLHEXOSAMINIDASE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; PHOSPHOLIPASE C; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DURA MATER; ENZYME INHIBITION; HEADACHE; IN VITRO STUDY; MALE; MAST CELL DEGRANULATION; MOLECULAR MECHANICS; NONHUMAN; PERITONEUM; RAT;

ANIMALS; CELL DEGRANULATION; DISEASE MODELS, ANIMAL; DURA MATER; MALE; MAST CELLS; MIGRAINE DISORDERS; PEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RATS; RATS, SPRAGUE-DAWLEY; VASOACTIVE INTESTINAL PEPTIDE; VASODILATOR AGENTS;

EID: 84858430436     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412439354     Document Type: Article

References (40)

1. Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci. 1994 ; 15: 149-153 (Pubitemid 24156497)
2. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002 ; 22: 54-61 (Pubitemid 34626025)
3. Wienecke T, Olesen J, Ashina M. Prostaglandin I(2) (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia. 2009 ; 30: 179-190
4. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostaglandin E2 (PGE2) induces headache in healthy subjects. Cephalalgia. 2009 ; 29: 509-519
5. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009 ; 132: 16-25
6. Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J, et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia. 1998 ; 18: 27-32 (Pubitemid 28096515)
7. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008 ; 372: 2115-2123
8. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 ; 350: 1104-1110 (Pubitemid 38298990)
9. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 2000 ; 52: 269-324 (Pubitemid 30368434)
10. Dickinson T, Fleetwood-Walker SM. VIP and PACAP: very important in pain?. Trends Pharmacol Sci. 1999 ; 20: 324-329 (Pubitemid 29368372)
11. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J, et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia. 2006 ; 26: 992-1003 (Pubitemid 44079724)
12. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. 2008 ; 28: 226-236 (Pubitemid 351172031)
13. Li M, Maderdrut JL, Lertora JJL, Batuman V. Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: A case study. Peptides. 2007 ; 28: 1891-1895 (Pubitemid 47361424)
14. Beaven MA. Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol. 2009 ; 39: 11-25
15. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005 ; 49: 65-76 (Pubitemid 40800163)
16. Warbrick EV, Taylor AM, Botchkarev VA, Coleman JW. Rat connective tissue-type mast cells express MHC class II: up-regulation by IFN-gamma. Cell Immunol. 1995 ; 163: 222-228
17. Haimart M, Pradalier A, Launay JM, Dreux C, Dry J. Whole blood and plasma histamine in common migraine. Cephalalgia. 1987 ; 7: 39-42
18. Heatley RV, Denburg JA, Bayer N, Bienenstock J. Increased plasma histamine levels in migraine patients. Clin Allergy. 1982 ; 12: 145-149 (Pubitemid 12157303)
19. Covelli V, Munno I, Pellegrino NM, Di VA, Jirillo E, Buscaino GA. Exaggerated spontaneous release of tumor necrosis factor-alpha/cachectin in patients with migraine without aura. Acta Neurol (Napoli). 1990 ; 12: 257-263
20. Monro J, Carini C, Brostoff J. Migraine is a food-allergic disease. Lancet. 1984 ; 2: 719-721 (Pubitemid 14037036)
21. Passante E, Ehrhardt C, Sheridan H, Frankish N. RBL-2H3 cells are an imprecise model for mast cell mediator release. Inflamm Res 2009; 58(9): 611-618.
22. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience. 1999 ; 89: 901-907 (Pubitemid 29071014)
23. Moro O, Lerner EA. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J Biol Chem. 1997 ; 272: 966-970 (Pubitemid 27035014)
24. Mori T, Kawashima T, Beppu Y, Takagi K. Histamine release induced by pituitary adenylate cyclase activating polypeptide from rat peritoneal mast cells. Arzneimittelforschung. 1994 ; 44: 1044-1046
25. Seebeck J, Kruse ML, Schmidt-Choudhury A, Schmidt WE. Pituitary adenylate cyclase activating polypeptide induces degranulation of rat peritoneal mast cells via high-affinity PACAP receptor-independent activation of G proteins. Ann N Y Acad Sci. 1998 ; 865: 141-146 (Pubitemid 29047821)
26. Reglodi D, Borzsei R, Bagoly T, Boronkai A, Racz B, Tamas A, et al. Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells. J Mol Neurosci. 2008 ; 36: 270-278
27. Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides. 2007 ; 28: 1631-1639 (Pubitemid 47371033)
28. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature. 1993 ; 365: 170-175 (Pubitemid 23282064)
29. Journot L, Waeber C, Pantaloni C, Holsboer F, Seeburg PH, Bockaert J, et al. Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor. Biochem Soc Trans. 1995 ; 23: 133-137
30. Ushiyama M, Ikeda R, Sugawara H, Yoshida M, Mori K, Kangawa K, et al. Differential intracellular signaling through PAC1 isoforms as a result of alternative splicing in the first extracellular domain and the third intracellular loop. Mol Pharmacol. 2007 ; 72: 103-111 (Pubitemid 46998529)
31. Delporte C, Poloczek P, de NP, Vertongen P, Ciccarelli E, Svoboda M, et al. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor. Mol Cell Endocrinol. 1995 ; 107: 71-76
32. Deutsch PJ, Sun Y. The 38-amino acid form of pituitary adenylate cyclase-activating polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth. J Biol Chem. 1992 ; 267: 5108-5113
33. Braas KM, May V. Pituitary adenylate cyclase-activating polypeptides directly stimulate sympathetic neuron neuropeptide Y release through PAC(1) receptor isoform activation of specific intracellular signaling pathways. J Biol Chem. 1999 ; 274: 27702-27710
34. Mazzocchi G, Malendowicz LK, Neri G, Andreis PG, Ziolkowska A, Gottardo L, et al. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland. Int J Mol Med. 2002 ; 9: 233-243
35. Tompkins J, Parsons R. Identification of intracellular signaling cascades mediating the PACAP-induced increase in guinea pig cardiac neuron excitability. J Mol Neurosci. 2008 ; 36: 292-298
36. Seydewitz V, Staubesand J. Immunocytochemical demonstration of lysosomal matrix vesicles in the arterial wall of the rat. Histochemistry. 1988 ; 88: 463-467 (Pubitemid 18086720)
37. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation. 1995 ; 2: 241-248 (Pubitemid 26082188)
38. Oka Y, Ibuki T, Matsumura K, Namba M, Yamazaki Y, Poole S, et al. Interleukin-6 is a candidate molecule that transmits inflammatory information to the CNS. Neuroscience. 2007 ; 145: 530-538 (Pubitemid 46341642)
39. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009 ; 132: 16-25
40. Azzolina A, Bongiovanni A, Lampiasi N. Substance P induces TNF-α and IL-6 production through NF+κB in peritoneal mast cells. Biochim Biophys Acta. 2003 ; 1643: 75-83 (Pubitemid 37494893)